论文部分内容阅读
利用计算机检索Cochrane Library,Web of Science,PubMed,FMJS,中国生物医学文献数据库,维普知识资源系统,中国期刊全文数据库,万方数据知识服务平台,检索时间从各数据库至截止2012年7月5日,同时辅助其他检索,纳入榄香烯联合铂类化疗药物治疗NSCLC的随机对照试验(randomized controlled trials,RCTs),由2名研究员分别独立提取数据和进行文献质量评价,并用RevMan 5.2软件进行Meta分析,系统评价榄香烯注射液联合铂类药物治疗非小细胞肺癌的疗效和安全性,共纳入11篇RCTs,共计病例数为844例,Meta分析结果显示,与单纯含铂类化疗药物相比,榄香烯注射液联合铂类化疗药物可以提高临床获益率(OR=2.03,95%CI:1.43～2.88,P<0.000 1)和生活质量(OR=3.23,95%CI:2.20～4.74,P<0.000 01);减少白细胞下降(OR=0.50,95%CI:0.33～0.76,P<0.001)、血小板下降(OR=0.38,95%CI:0.16～0.85,P<0.02)、提高CD4(MD=3.32,95%CI:2.94～3.70,P<0.000 01),和CD4/CD8(MD=0.36,95%CI:0.28～0.44,P<0.000 01),降低恶心呕吐等胃肠道反应(OR=0.37,95%CI:0.19～0.71,P=0.003)。该文分析提示榄香烯能提高非小细胞肺癌化疗效果,改善生活质量,并降低铂类化疗药物的毒副作用,值得临床推广使用。
Using computer to search Cochrane Library, Web of Science, PubMed, FMJS, Chinese Biomedical Literature Database, VIP Information Resource System, Chinese Journal Full-text Database, Wanfang Data Knowledge Service Platform, and search time from each database to July 5, 2012 , And assisted with other searches. Randomized controlled trials (RCTs) of elemene combined with platinum-based chemotherapeutic agents for the treatment of NSCLC were performed. Data were independently extracted and quality evaluated by two investigators. Meta-analysis was performed using RevMan 5.2 software , A systematic review of the efficacy and safety of elemene injection combined with platinum-based drug in the treatment of non-small cell lung cancer. A total of 11 RCTs were enrolled in this study. The total number of cases was 844. Meta analysis showed that, compared with platinum-containing chemotherapy alone , Elemene injection combined with platinum chemotherapy drugs can improve the clinical benefit rate (OR = 2.03, 95% CI: 1.43-2.88, P <0.0001) and quality of life (OR = 3.23, 95% CI: 2.20-4.74 , P <0.000 01); decreased leukopenia (OR = 0.50, 95% CI: 0.33-0.76, P <0.001) and thrombocytopenia (OR = 0.38, 95% CI 0.16-0.85, P <0.02) (MD = 3.32, 95% CI: 2.94-3.70, P <0.000 01), and CD4 / CD 8 (MD = 0.36, 95% CI: 0.28-0.44, P <0.000 01), reducing nausea and vomiting and other gastrointestinal reactions (OR = 0.37, 95% CI: 0.19-0.71, P = 0.003). The analysis suggests that elemene can improve the chemotherapy effect of non-small cell lung cancer, improve the quality of life, and reduce the toxic side effects of platinum chemotherapy drugs, worthy of clinical promotion.